Search
Search Results
-
Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study
BackgroundThe multikinase inhibitors (MKIs) sorafenib, lenvatinib, and vandetanib are approved for advanced thyroid cancer (TC) in Japan. How...
-
Neoadjuvant Multikinase Inhibitor Therapy in Locally Advanced Unresectable Differentiated Thyroid Carcinoma: a Case Report
Multikinase or tyrosine kinase inhibitors (TKI) are currently approved for radioiodine-refractory metastatic differentiated thyroid carcinoma...
-
Long-term response to MEK inhibitor monotherapy in a patient with papillary thyroid carcinoma harboring BRAF V600E mutation
Solid tumors harboring mutations in the Braf gene ( BRAF ) are currently treated by combination Braf/MEK inhibitor therapy, and there is an extensive...
-
Multikinase inhibitors in thyroid cancer: timing of targeted therapy
In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer with multikinase inhibitors, much has changed in the...
-
Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
In our phase Ib trial (ClinialTrials.gov Identifier: NCT03855358), benmelstobart (TQB2450), a novel humanized IgG1 antibody against PD-L1, plus...
-
Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real‐world treatment outcomes
Purpose Despite the established activity of regorafenib in metastatic colorectal cancer (CRC), gastrointestinal stromal tumor (GIST), and...
-
AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis
Despite the great advances in the understanding of the molecular basis of acute leukemia, very little of this knowledge has been translated into new...
-
Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma
Purpose Axitinib is an orally active multikinase inhibitor currently used to treat patients with metastatic renal cell carcinoma (RCC). This study...
-
Proteinuria reduction with SGLT2 inhibitors in a patient treated with tyrosine kinase inhibitor lenvatinib
We describe the case of a 66-year-old woman treated with tyrosine kinase inhibitor Lenvatinib for thyroid carcinoma who had persistent proteinuria...
-
Ten years’ real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer
PurposeTo evaluate objective response rates (ORR), progression-free survival (PFS), and overall survival (OS) associated with tyrosine kinase...
-
-
Severe hypertension development significantly improves progression-free survival in regorafenib treatment for metastatic colorectal cancer
PurposeRegorafenib is the first multikinase inhibitor used for metastatic colorectal cancer (mCRC) treatment. Reports regarding other multikinase...
-
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
MEK inhibitors have immunomodulatory activity and potential for synergistic activity when combined with PD-1 inhibitors. We evaluated selumetinib...
-
Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives
Metastatic gastric and gastroesophageal junction cancers have been treated with chemotherapy, but the landscape of cancer treatment is rapidly...
-
Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinib
Background/AimLenvatinib, a multikinase inhibitor, has become a second-line treatment option for unresectable liver cancer, while its monotherapy...
-
New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally and is rising in incidence. Until recently, treatment options for patients...
-
Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle
Anaplastic thyroid cancer (ATC) represents the type with the worst prognosis among thyroid cancers. In ATC with a highly invasive phenotype,...
-
Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: a case report and literature review
Entrectinib, a multikinase inhibitor of ROS1 and tropomyosin receptor kinases, is recommended to treat ROS1 -positive metastatic non-small cell lung...
